Inclusion Criteria:

- Histological or cytological diagnosis of adenocarcinoma of the prostate

- Metastatic or locally recurrent disease not curable with standard therapy

- ECOG performance status 0, 1 or 2

- Prior single agent docetaxel or docetaxel combination chemotherapy with a documented
PSA or imaging response, and no objective evidence of disease progression at study
enrolment

Exclusion Criteria:

- Patients with a history of other invasive cancer, except adequately treated non

- melanoma skin cancer.

- Patients with known brain metastases.

- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to SU011248.

- Other serious intercurrent illness or medical condition that might be aggravated by
protocol treatment.